Refine by
Gut Microbiome Articles & Analysis
64 news found
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. ...
Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the standard for next-generation routine microbiome analysis with its Precision Microbiome Profiling (PMP™) platform. ...
ByBio-Me
His groundbreaking work established several key concepts in the biology of the gut-brain axis and its influence on complex behaviors and brain function, including how the gut microbiome may impact certain characteristics in people with Autism Spectrum Disorder (ASD). ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). ...
(California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD Bioscience advance prebiotics platform will open new avenues ...
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome. James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain control and novel ...
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
The paper, “A gut-derived metabolite alters brain activity and anxiety behavior in mice,” offers new mechanistic insight into how the gut microbiome can influence complex behaviors via the gut-brain axis. ...
“The data highlighted in Nature Medicine further support our novel therapeutic strategy focused on specific targets in the gut microbiome. We strongly believe that AB-2004 can improve the quality of life of many children with ...
GutFlora Omics Platform recently announced the launch of virome sequencing service to better study gut microbiota. The gut microbiome includes a huge number of bacteria, archaea, fungi, and enteroviruses that colonize the gut. At present, most of the research on gut microbes focuses on the study of bacteria, ...
Through long-term and detailed studies of the gut microbiota, scientists have revealed the complex relationship between human and gut microbes. ...
About AB-2004 AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in autism. AB-2004 has a unique mechanism of action that selectivity sequesters certain bacterially derived metabolites in the gut before they enter the bloodstream and reach the brain. ...
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its ...
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. ...
” AB-2004: Novel Small Molecule Therapy with Defined Mechanism of Action AB-2004 is a first-in-class, molecular therapeutic that targets the microbiome gut-brain axis and its role in autism. AB-2004 has a unique mechanism of action that selectivity sequesters certain bacterially derived metabolites in the gut before they enter the ...
Sarkis Mazmanian at the California Institute of Technology, whohas elucidated clear biological links implicating the gut microbiome, via the gut-brain axis, in serious neurological conditions. ...
“We believe these results are an important step forward for the prevention of C. difficile infection and the microbiome field at large. These data substantially add to the evidence in support of a therapeutic approach that bypasses the use of fecal donations or their spore fractions. ...
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with ...
Metabolomics is the study of metabolite changes in organisms, which can provide information on the metabolism of microorganisms in the gut. By detecting metabolites in various body fluids (e.g., urine, plasma, and feces), functional profiles of common metabolites of gut microbes and hosts can be obtained, which can help to study metabolic pathways affected by ...